

SITC 2016

NATIONAL HARBOR, MD

NOVEMBER 9–13, 2016

New Cancer Immunotherapy Agents in Development

Wednesday, November 9, 2016

Primer on Tumor Immunology and Cancer Immunotherapy™

Thursday, November 10, 2016

Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy

Thursday, November 10, 2016

31st Annual Meeting

Friday, November 11–Sunday, November 13, 2016

Value of Cancer Immunotherapy Summit

Organized in Collaboration with the American Society of Clinical Oncology (ASCO)

Sunday, November 13, 2016



Society for Immunotherapy of Cancer



New Cancer Immunotherapy Agents in Development

Wednesday, November 9, 2016

Co-Chairs:

Adrian Bot, MD, PhD – *Kite Pharma, Inc.*

Daniel S. Chen, MD, PhD – *Genentech*

Roger D. Dansey, MD – *Merck & Co., Inc.*

Michelle Dawson, PhD – *Bristol-Myers Squibb*

Ramy Ibrahim, MD* – *The Parker Institute for Cancer Immunotherapy*

*Formerly at *AstraZeneca*

Salil Patel, PhD – *Bristol-Myers Squibb* (Acting Co-Chair)

11:00 – 11:10 a.m. **Welcome & Introductions**

Session I: New Agents in Development

11:10 – 12:20 p.m. **Various presentations from companies on the following targets: LAG3, Tim-3, 4-1BB, OX40, CD40, IDO, GITR, ICOS, CSF-1R, CCR4, T Cell Bispecific, CAR-T, TCR-T, Vaccines**
If you would like to present on a new cancer immunotherapy in development, [click here](#).

12:20 – 12:45 p.m. **Audience Questions & Answers**

12:45 – 1:30 p.m. *Lunch*

Session II: Strategic Considerations of Combinations and Biomarkers in New Agent Development

1:30 – 2:00 p.m. **Combinations & Biomarkers**

2:00 – 3:25 p.m. **Panel Discussion**

3:25 – 3:30 p.m. **Closing Remarks**

Social Activity

3:30 – 4:30 p.m. *Drug Development Networking Reception*



Primer on Tumor Immunology and Cancer Immunotherapy™

Thursday, November 10, 2016

8:00 – 8:10 a.m.

Welcome & Introductions

Margaret K. Callahan, MD, PhD – *Memorial Sloan Kettering Cancer Center*

Session I: Basic Immunology – A Brief Overview

2 AMA PRA Category 1 Credits™

8:10 – 8:45 a.m.

Introduction to Innate Immunity

Miriam Merad, MD, PhD – *Icahn School of Medicine at Mount Sinai*

8:45 – 9:20 a.m.

Overview of Adaptive Immunity

Jonathan Powell, MD, PhD – *Johns Hopkins Hospital*

9:20 – 9:55 a.m.

Obstacles to Driving an Immune Response

Nicholas Arpaia, PhD – *Memorial Sloan Kettering Cancer Center*

9:55 – 10:10 a.m.

Panel Questions & Answers

10:10 – 10:25 a.m.

Break

Session II: Treating Tumors with Passive Immunotherapy

2 AMA PRA Category 1 Credits™

10:25 – 10:30 a.m.

Session II Introduction

Margaret K. Callahan, MD, PhD – *Memorial Sloan Kettering Cancer Center*

10:30 – 11:05 a.m.

Adoptive T Cell Therapy

Saar I. Gill, MD, PhD – *University of Pennsylvania*

11:05 – 11:40 a.m.

Anti-Tumor Antibody/Bispecifics

Charles G. Drake, MD, PhD – *Johns Hopkins University*

11:40 – 12:15 p.m.

Immune Modulators: Cytokines and Beyond

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

12:15 – 12:30 p.m.

Panel Questions & Answers

12:30 – 1:30 p.m.

Lunch



Session III: Active Immunotherapy – Unleashing the Patient’s Own Immune System

1.5 AMA PRA Category 1 Credits™

- | | |
|------------------|--|
| 1:30 – 1:35 p.m. | Session III Introduction
Nina Bhardwaj, MD, PhD – <i>The Tisch Cancer Institute at The Mount Sinai Medical Center</i> |
| 1:35 – 2:10 p.m. | Cancer Vaccines
Patrick Ott, MD, PhD – <i>Dana-Farber Cancer Institute, Harvard Medical School</i> |
| 2:10 – 2:45 p.m. | Targeting Regulatory Molecules in Cancer Therapy: New Insights and Opportunities
Michael A. Curran, PhD – <i>University of Texas MD Anderson Cancer Center</i> |
| 2:45 – 3:00 p.m. | Panel Questions & Answers |
| 3:00 – 3:15 p.m. | <i>Break</i> |

Session IV: Figuring out How it All Works and Future Directions

1.75 AMA PRA Category 1 Credits™

- | | |
|------------------|--|
| 3:15 – 3:20 p.m. | Session IV Introduction
Nina Bhardwaj, MD, PhD – <i>The Tisch Cancer Institute at The Mount Sinai Medical Center</i> |
| 3:20 – 3:55 p.m. | Immune Monitoring and Next Generation
Sacha Gnajatic, PhD – <i>Icahn School of Medicine at Mount Sinai</i> |
| 3:55 – 4:30 p.m. | Novel Avenues Just Hitting the Clinic (Tumor Sequencing, Biomarkers, Hot Topics)
Mark M. Davis, PhD – <i>Stanford University School of Medicine, Howard Hughes Medical Institute</i> |
| 4:30 – 4:45 p.m. | Panel Questions & Answers |
| 4:45 – 5:00 p.m. | Closing Remarks
Nina Bhardwaj, MD, PhD – <i>The Tisch Cancer Institute at The Mount Sinai Medical Center</i> |

Social Activity

- | | |
|------------------|--|
| 5:30 – 6:30 p.m. | <i>Presidential Reception & State of SITC: Membership Business Meeting</i> |
|------------------|--|



Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy

Thursday, November 10, 2016

8:00 – 8:05 a.m.

Welcome & Introductions

Andrew Zloza, MD, PhD – *Rutgers Cancer Institute of New Jersey*

Session I: Introduction to Models of Immunotherapy

1.75 AMA PRA Category 1 Credits™

8:05 – 8:30 a.m.

Major Questions Related to Immunotherapies that Require Models to Address

Mario Sznol, MD – *Yale School of Medicine*

8:30 – 8:55 a.m.

Overview of Mouse-Mouse Models

Marcus Bosenberg, MD, PhD – *Yale School of Medicine*

8:55 – 9:20 a.m.

Overview of Humanized Mice Models

A. Karolina Palucka, MD, PhD – *The Jackson Laboratory for Genomic Medicine*

9:20 – 9:45 a.m.

Overview of Patient-derived Xenograft (PDX) Models

Andrew Zloza, MD, PhD – *Rutgers Cancer Institute of New Jersey*

9:45 – 10:15 a.m.

Break

Session II: Modeling the Tumor Microenvironment

1.75 AMA PRA Category 1 Credits™

10:15 – 10:40 a.m.

Evaluation of the Tumor Microenvironment

Mark B. Headley, PhD – *University of California San Francisco*

10:40 – 11:05 a.m.

Factors Affecting Tumor – Microenvironment Interactions

Lisa M. Coussens, PhD – *Oregon Health and Sciences University*

11:05 – 11:30 a.m.

Vascular Regulation of the Tumor Microenvironment and Immune Responses

Gwendalyn J. Randolph, PhD – *Washington University School of Medicine*

11:30 – 11:55 a.m.

Components of the Tumor Microenvironment that Module Tumor Immune Responses

Kwok-Kin Wong, MD, PhD – *Dana-Farber Cancer Institute, Harvard Medical School*

11:55 – 12:45 p.m.

Lunch



Session III: Modeling Evaluation of Immune Therapies

1.5 AMA PRA Category 1 Credits™

- | | |
|--|---|
| 12:45 – 1:15 p.m. | Evaluation of Immune Checkpoint Inhibitors in Mice
Arlene Sharpe, MD, PhD – <i>Harvard Medical School</i> |
| 1:15 – 1:45 p.m. | Reevaluating the Role of IDOI in Brain Cancer; Humanized Immunocompetent Mice Take Center Stage
Derek Wainwright, PhD – <i>Northwestern University</i> |
| 1:45 – 2:15 p.m. | Developing New Immune Therapies in Models and Humans
Elizabeth M. Jaffee, MD – <i>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</i> |
| 2:15 – 2:45 p.m.
<i>Non-CE Presentation</i> | What Information Provided by Models will Inform Immune Drug Development and Use?
Philip Gotwals, PhD – <i>Novartis Institutes for BioMedical Research, Inc.</i> |
| 2:45 – 3:15 p.m. | <i>Break</i> |

Session IV: Panel Discussion and Future Directions

- | | |
|---|---|
| 3:15 – 4:45 p.m.
<i>Non-CE Session</i> | Future Directions for the Development and Use of Cancer Immune Models
<i>Moderator:</i>
Marcus W. Bosenberg, MD, PhD – <i>Yale School of Medicine</i>

<i>Panelists:</i>
Lisa L. Coussens, PhD – <i>Oregon Health and Sciences University</i>
Philip Gotwals, PhD – <i>Novartis Institutes for BioMedical Research, Inc.</i>
Elizabeth M. Jaffee, MD – <i>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</i>
A. Karolina Palucka, MD, PhD – <i>The Jackson Laboratory for Genomic Medicine</i>
Arlene Sharpe, PhD – <i>Harvard Medical School</i>
Mario Sznol, MD – <i>Yale School of Medicine</i>
Kwok-Kin Wong, MD, PhD – <i>Dana-Farber Cancer Institute, Harvard Medical School</i>
Andrew Zloza, MD, PhD – <i>Rutgers Cancer Institute of New Jersey</i> |
| 4:45 – 5:00 p.m. | Closing Remarks
Marcus W. Bosenberg, MD, PhD – <i>Yale School of Medicine</i> |

Social Activity

- | | |
|------------------|--|
| 5:30 – 6:30 p.m. | <i>Presidential Reception & State of SITC: Membership Business Meeting</i> |
|------------------|--|



31st Annual Meeting

Friday, November 11, 2016

7:30 – 7:55 a.m. **Presidential Welcome & Holbrook Edwin Kidd Kohrt, MD, PhD Tribute**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Update Session

Non-CE Session

7:55 – 8:25 a.m. **Cancer Immunotherapy Trials Network (CITN)**

Keynote Address

Non-CE Session

8:25 – 8:30 a.m. **Introduction**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

8:30 – 9:05 a.m. **The Mechanistic Basis of Cancer Immunotherapy**
Ira Mellman, PhD – *Genentech*

9:05 – 9:10 a.m. **Question & Answer**
Ira Mellman, PhD – *Genentech*

Tumor Microenvironment

2.25 AMA PRA Category 1 Credits™

Co-Chairs:

Thomas F. Gajewski, MD, PhD – *University of Chicago*

Mary L. (Nora) Disis, MD – *University of Washington*

9:10 – 9:15 a.m. **Introduction**
Thomas F. Gajewski, MD, PhD – *University of Chicago*

9:15 – 9:40 a.m. **Biology of the Tumor Microenvironment**
Melody Swartz, PhD – *University of Chicago*

9:40 – 10:05 a.m. **Tumor Microenvironment with Clinical Aspect; Impact of Therapeutics on Microenvironment**
George Coukos, MD, PhD – *University Hospital of Lausanne*

10:05 – 10:25 a.m. *Break*

10:25 – 10:50 a.m. **TBD**
Thomas F. Gajewski, MD, PhD – *University of Chicago*

10:50 – 11:10 a.m. **CD4 T Cells as Regulators of Tumor Growth**
Mary (Nora) L. Disis, MD – *University of Washington*

11:10 – 11:25 a.m. **Oral Abstract 1**

11:25 – 11:40 a.m. **Oral Abstract 2**

11:40 – 11:45 a.m. **Closing Remarks**
Mary (Nora) L. Disis, MD – *University of Washington*



Late-Breaking Abstract Session I

Non-CE Session

11:45 – 12:15 p.m. **Oral Abstract Presentations**

12:15 – 1:30 p.m. *Lunch and Poster Viewing*

Update Session

.5 AMA PRA Category 1 Credits™

1:30 – 2:00 p.m. **Government Agencies**

State-of-the-Art Immunotherapies: Challenges and Opportunities

2.25 AMA PRA Category 1 Credits™

Co-Chairs:

James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institutes of Health*

Roy S. Herbst, MD, PhD – *Yale Cancer Center*

2:00 – 2:05 p.m. **Introduction**
Roy S. Herbst, MD, PhD – *Yale Cancer Center*

2:05 – 2:30 p.m. **Lung Cancer: Challenges and Opportunities**
Roy S. Herbst, MD, PhD – *Yale Cancer Center*

2:30 – 2:55 p.m. **Melanoma: Challenges and Opportunities**
Patrick Hwu, MD – *University of Texas MD Anderson Cancer Center*

2:55 – 3:20 p.m. **Translational Development of Novel Immunotherapies for Hematologic Cancers**
Larry W. Kwak, MD, PhD – *City of Hope National Medical Center*

3:20 – 3:45 p.m. **Challenges and Opportunities for Immunotherapy in Prostate Cancer**
James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institutes of Health*

3:45 – 4:00 p.m. **Oral Abstract 1**

4:00 – 4:15 p.m. **Oral Abstract 2**

4:15 – 4:45 p.m. *Break*

Concurrent Session 1: Metabolic and Age-Associated Dysregulation of Anti-Cancer Immunity

1.5 AMA PRA Category 1 Credits™

Organized in collaboration with the American Society for Cell Biology

Co-Chairs:

Graham M. Pawelec, PhD – *University of Tuebingen*

Tom Misteli, PhD – *National Cancer Institute, National Institutes of Health*

4:45 – 4:50 p.m. **Introduction**
Graham M. Pawelec, PhD – *University of Tuebingen*

4:50 – 5:15 p.m. **The Immune System Strikes Back: T Cells Recognizing Indoleamine 2,3-Dioxygenase (IDO) or PD-L1**
Mads Hald Andersen, PhD – *Herlev University Hospital*



5:15 – 5:40 p.m. **Myeloid-Derived Suppressor Cells (MDSC), Age and Cancer**
Dawn Bowdish, PhD – *McMaster University*

5:40 – 5:55 p.m. **Oral Abstract 1**

5:55 – 6:10 p.m. **Oral Abstract 2**

Concurrent Session II: Promoting and Measuring Anti-Tumor Immunity

1.5 AMA PRA Category 1 Credits™

Co-Chairs:

Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*

Francesco M. Marincola, MD – *Sidra Medical and Research Center*

4:45 – 4:50 p.m. **Introduction**
Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*

4:50 – 5:10 p.m. **Immunotherapeutics and Analyses of the Peripheral Immunome**
Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*

5:10 – 5:30 p.m. **Vaccines, Tumor Antigens, and Immune Responses**
Lisa H. Butterfield, PhD – *University of Pittsburgh*

5:30 – 5:50 p.m. **Deciphering Human T Cell Immune Responses Modulated with Immunotherapy**
Lawrence Fong, MD – *University of California San Francisco*

5:50 – 6:05 p.m. **Oral Abstract 1**

6:05 – 6:10 p.m. **Closing Remarks**
Francesco M. Marincola, MD – *Sidra Medical and Research Center*

6:15 – 7:30 p.m. *Poster Reception*

Saturday, November 12, 2016

7:30 – 7:40 a.m. **Immune Biomarkers Task Force Update**
Lisa H. Butterfield, PhD – *University of Pittsburgh*

7:40 – 7:55 a.m. **Immunoscore Update**

Smalley Keynote Address

1.0 AMA PRA Category 1 Credits™

7:55 – 8:00 a.m. **Introduction**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

8:00 – 8:35 a.m. **Smalley Keynote Address: PD-1 Blockade in Cancer Treatment – Immunotherapy Meets Precision Medicine**
Suzanne L. Topalian, MD – *Johns Hopkins University*

8:35 – 8:40 a.m. **Question & Answer**
Suzanne L. Topalian, MD – *Johns Hopkins University*



Beyond Single-Agents: The Future of Combination Immunotherapy

2.25 AMA PRA Category 1 Credits™

Co-Chairs:

Drew M. Pardoll, MD, PhD – *Johns Hopkins University*

F. Stephen Hodi, MD – *Dana-Farber Cancer Institute*

Holbrook E. Kohrt, MD, PhD* – *Stanford Cancer Institute*

8:40 – 8:45 a.m.	Introduction F. Stephen Hodi, MD – <i>Dana-Farber Cancer Institute</i>
8:45 – 9:10 a.m.	Combination Development Ignacio Melero, MD, PhD – <i>University of Navarra</i>
9:10 – 9:35 a.m.	Combination in Clinical Trials Alan J. Korman, PhD – <i>Bristol-Myers Squibb Company</i>
9:35 – 10:00 a.m.	Combination in Patient Selection Jerome Galon, PhD – <i>INSERM-Cordeliers Research Center</i>
10:00 – 10:20 a.m.	<i>Break</i>
10:20 – 10:40 a.m.	Combinations and Influences on Biomarkers Drew M. Pardoll, MD, PhD – <i>Johns Hopkins University</i>
10:40 – 10:55 a.m.	Oral Abstract 1
10:55 – 11:10 a.m.	Oral Abstract 2
11:10 – 11:15 a.m.	Closing Remarks Drew M. Pardoll, MD, PhD – <i>Johns Hopkins University</i>

Late-Breaking Abstract Session II

Non-CE Session

11:15 – 11:45 a.m.	Oral Abstract Presentations
11:45 – 1:00 p.m.	<i>Lunch and Poster Viewing</i>

Concurrent Session I: Presidential Session

1.5 AMA PRA Category 1 Credits™

Chair:

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

1:00 – 1:05 p.m.	Introduction Howard L. Kaufman, MD, FACS – <i>Rutgers Cancer Institute of New Jersey</i>
1:05 – 1:20 p.m.	Oral Abstract 1
1:20 – 1:35 p.m.	Oral Abstract 2
1:35 – 1:45 p.m.	Expert Discussant Drew M. Pardoll, MD, PhD – <i>Johns Hopkins University</i>



- 1:45 – 2:00 p.m. **Oral Abstract 3**
- 2:00 – 2:15 p.m. **Oral Abstract 4**
- 2:15 – 2:25 p.m. **Expert Discussant**
 Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*

Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track)

1.5 AMA PRA Category 1 Credits™

Co-Chairs:

Paul M. Sondel, MD, PhD – *University of Wisconsin – Madison*

Satiro De Oliveira, MD – *University of California Los Angeles*

- 1:00 – 1:05 p.m. **Introduction**
 Paul M. Sondel, MD, PhD – *University of Wisconsin – Madison*
- 1:05 – 1:30 p.m. **Immunology 101 for the Non-Immunologist**
 Christian Capitini, MD – *University of Wisconsin – Madison*
- 1:30 – 1:55 p.m. **Basic Principles of Tumor Immunotherapy**
 Satiro N. De Oliveira, MD – *University of California Los Angeles*
- 1:55 – 2:20 p.m. **Tumor Immunotherapy on the Horizon**
 Paul M. Sondel, MD, PhD – *University of Wisconsin – Madison*
- 2:20 – 2:25 p.m. **Closing Remarks**
 Satiro N. De Oliveira, MD – *University of California Los Angeles*
- 2:25 – 2:40 p.m. *Break*

Concurrent Session I: Microbiome and the Impact on Local Inflammation and Host Immunity

1.75 AMA PRA Category 1 Credits™

Co-Chairs:

Lisa M. Coussens, PhD – *Oregon Health and Science University*

Heidi H. Kong, MD, MHSc – *National Cancer Institute, National Institutes of Health*

- 2:40 – 2:45 p.m. **Introduction**
 Heidi H. Kong, MD, MHSc – *National Cancer Institute, National Institutes of Health*
- 2:45 – 3:05 p.m. **Microbial Modulation of Mononuclear Phagocytes in Cancer Therapy**
 Romina Goldszmid, PhD – *National Cancer Institute, National Institutes of Health*
- 3:05 – 3:25 p.m. **Influence of Microbiome on Efficacy of Anti-Cancer Therapy**
 María Paula Roberti, PhD – *Institute Gustave Roussy*
- 3:25 – 3:45 p.m. **Effect of Acute Infection on Tissue-Specific Immunity**
 Christian Jobin, PhD – *University of Florida*
- 3:45 – 4:00 p.m. **Oral Abstract 1**
- 4:00 – 4:15 p.m. **Oral Abstract 2**
- 4:15 – 4:20 p.m. **Closing Remarks**
 Lisa M. Coussens, PhD – *Oregon Health and Science University*



Concurrent Session II: Clinical Management (Nurse/Pharmacist Track)

1.75 AMA PRA Category 1 Credits™

Co-Chairs:

Laura S. Wood, RN, MSN OCN – *Cleveland Clinic Taussig Cancer Institute*

Matthew Burke, MBA, RN, MSN, APRN-B – *Stanford Health Care*

- | | |
|------------------|--|
| 2:40 – 2:45 p.m. | Introduction
Laura S. Wood, RN, MSN OCN – <i>Cleveland Clinic Taussig Cancer Institute</i> |
| 2:45 – 3:05 p.m. | Overview of Approved Immunotherapy Approaches
Kristen Kreamer, CRNP, MSN, AOCNP, APRN-BC – <i>Fox Chase Cancer Center</i> |
| 3:05 – 3:25 p.m. | Assessment & Management of irAEs
Krista M. Rubin, MS, FNP-BC – <i>Massachusetts General Hospital</i> |
| 3:25 – 3:45 p.m. | Management of Complex Adverse Events: Case Studies
Brianna W. Hoffner, BA, MSN, RN, ANP-BC – <i>University of Colorado</i> |
| 3:45 – 4:00 p.m. | Oral Abstract 1 |
| 4:00 – 4:15 p.m. | Panel Discussion/Additional Case Study
Moderator: Matthew Burke, MBA, RN, MSN, APRN-B – <i>Stanford Health Care</i> |
| 4:15 – 4:20 p.m. | Closing Remarks
Matthew Burke, MBA, RN, MSN, APRN-B – <i>Stanford Health Care</i> |
| 4:20 – 4:50 p.m. | <i>Break</i> |

Concurrent Session I: Diet, Exercise, Stress and the Impact on the Immune System

1.5 AMA PRA Category 1 Credits™

Organized in collaboration with the Society of Behavioral Medicine

Co-Chairs:

Elizabeth A. Repasky, PhD – *Roswell Park Cancer Institute*

Connie J. Rogers, PhD, MPH – *Pennsylvania State University*

- | | |
|------------------|---|
| 4:50 – 4:55 p.m. | Introduction
Connie J. Rogers, PhD, MPH – <i>Pennsylvania State University</i> |
| 4:55 – 5:15 p.m. | Changes in Energy Balance to Modulate the Immune Response in Breast Cancer Risk & Progression
Connie J. Rogers, PhD, MPH – <i>Pennsylvania State University</i> |
| 5:15 – 5:35 p.m. | Research in Behavior in Cancer and Cancer Treatment
Dana H. Bovbjerg, PhD – <i>University of Pittsburgh Cancer Institute</i> |
| 5:35 – 5:55 p.m. | Effects of Psychological Stress on Inflammation and Tumor Biology
Susan K. Lutgendorf, PhD – <i>University of Iowa</i> |
| 5:55 – 6:10 p.m. | Oral Abstract 1 |
| 6:10 – 6:15 p.m. | Closing Remarks
Elizabeth A. Repasky, PhD – <i>Roswell Park Cancer Institute</i> |



Concurrent Session II: Adoptive Cellular Therapy vs. Bispecific Antibodies

1.5 AMA PRA Category 1 Credits™

Co-Chairs:

Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

Crystal L. Mackall, MD – *Stanford University*

- | | |
|------------------|--|
| 4:50 – 4:55 p.m. | Introduction
Crystal L. Mackall, MD – <i>Stanford University</i> |
| 4:55 – 5:15 p.m. | CARs - CD19 and Beyond
Crystal L. Mackall, MD – <i>Stanford University</i> |
| 5:15 – 5:35 p.m. | Bispecific T Cell Engagers, Biology and Clinical Application
Max S. Topp, MD – <i>Universitätsklinikum Würzburg</i> |
| 5:35 – 5:55 p.m. | CAR Designs for Safe and Effective T Cell Therapy
Stanley R. Riddell, MD – <i>Fred Hutchinson Cancer Research Center</i> |
| 5:55 – 6:10 p.m. | Oral Abstract 1 |
| 6:10 – 6:15 p.m. | Closing Remarks
Stanley R. Riddell, MD – <i>Fred Hutchinson Cancer Research Center</i> |

Concurrent Session III: Emerging Technologies

Non-CE Session

Co-Chairs:

David A. Zaharoff, PhD – *University of North Carolina - Chapel Hill & North Carolina State University*

Edward C. Stack, PhD – *PerkinElmer*

- | | |
|-------------------|--|
| 4:50 – 4:55 p.m. | Introduction
Edward C. Stack, PhD – <i>PerkinElmer</i> |
| 4:55 – 5:20 p.m. | Understanding T Cells, Macrophages, and Expression of PD-1/PD-L1 in Hodgkin's Lymphoma
Scott J. Rodig, MD, PhD – <i>Brigham and Women's Hospital, Harvard Medical School</i> |
| 5:20 – 5:40 p.m. | Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity
Darrell J. Irvine, PhD – <i>Massachusetts Institute of Technology</i> |
| 5:40 – 5:55 p.m. | Oral Abstract 1 |
| 5:55 – 6:10 p.m. | Oral Abstract 2 |
| 6:10 – 6:15 p.m. | Closing Remarks
David A. Zaharoff, PhD – <i>University of North Carolina - Chapel Hill & North Carolina State University</i> |
| 6:15 – 6:45 p.m. | <i>Award Ceremony</i> |
| 6:45 – 8:00 p.m. | <i>Poster Reception</i> |
| 8:30 – 11:30 p.m. | <i>The CheckPoints Party</i> |



Value of Cancer Immunotherapy Summit

Organized in Collaboration with the American Society of Clinical Oncology (ASCO)

Sunday, November 13, 2016

7:45 – 7:50 a.m. **Annual Meeting Organizer Welcome**
Elizabeth A. Repasky, PhD – *Roswell Park Cancer Institute*

7:50 – 8:00 a.m. **Program Introduction**

Session I: : Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective

8:00 – 8:45 a.m. **Evaluation of Current Value Models and Cancer Immunotherapy Perspectives**

8:45 – 9:05 a.m. **Economic Outcomes of Cancer Therapy**

9:05 – 9:25 a.m. **Patient Perspective**

9:25 – 9:45 a.m. **Panel Discussion**

9:45 – 10:00 a.m. *Break*

Session II: Perspectives on the Value of Cancer Immunotherapy

10:00 – 10:20 a.m. **Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer**

10:20 – 10:40 a.m. **Payor Perspective**

10:40 – 11 a.m. **Industry Perspective**

11 – 11:20 a.m. **Predictive and Companion Biomarkers**

11:20 – 11:55 a.m. **Panel Discussion**

11:55 – Noon **Closing Remarks**

**Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)*

Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC. Dr. Kohrt was actively involved in the development of SITC's 31st Annual Meeting as an Organizer and session Co-Chair up until the time of passing. As such, the 31st Annual Meeting will contain a fitting tribute to his memory and his many contributions to the field.